Risk Stratification in Multiple Myeloma
New innovative therapies in MM have increased significantly over the past decade and have improved survival rates. Options now include proteasome inhibitors, immunomodulatory agents, HDAC inhibitors, monoclonal antibodies as well as standard chemotherapy. This activity equips the AP with critical updates in NCCN guidelines, diagnosis, risk-stratification, and treatment options, including: mechanism of action, side effect profile and supportive care.
Posted: February 28, 2016 / Expires: February 28, 2017
Credits/Contact Hours: 1.0
Watch Video Without Claiming Credit
* This link will take you to the Meniscus
Educational Institute website.